TCTMD

Elixir Medical Announces Schedule of Programs for TCT 2014

First Live Case Transmission in the US of the CE Mark-approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System Sunnyvale, CA—Elixir Medical Corporation, a developer of ...
Yahoo

TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50%

Elixir Medical's DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Image credit: Jo Panuwat D via Shutterstock.com. Elixir Medical’s ...
TCTMD

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a ...
Business Wire

Elixir Medical Expands Leadership Team With Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President ...
Business Wire

Elixir Medical Strengthens Its Commercial Capabilities With the Addition of Alaeddin Ahram as Executive Vice President, International

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, ...
Seeking Alpha

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES— —Significantly lower ...
Business Insider

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...
BioWorld

Data shows Elixir’s coronary implant with TRx coating is safe

Elixir Medical Corp. reported positive 12-month clinical data from the Desyne BDS Plus randomized controlled trial which evaluated its Desyne BDS plus system, a triple drug-eluting coronary implant ...
Yahoo Finance

Elixir Medical Highlights Results From “Real World” MY-IVL Study Demonstrating Performance of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in ...

MILPITAS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, announced results from the MY-IVL Study at the Transcatheter ...
BioWorld

Items Tagged with 'Elixir Medical Corp.'

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...
Nature

Elixir Medical Corporation

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...